United States - English - NLM (National Library of Medicine)

bryant ranch prepack - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. use in pregnancy: routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnan

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - econazole nitrate (unii: h438wyn10e) (econazole - unii:6z1y2v4a7m) - econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by trichophyton rubrum, trichophyton mentagrophytes, trichophyton tonsurans, microsporum canis, microsporum audouini, microsporum gypseum, and epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. econazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of its ingredients.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - naftifine hydrochloride (unii: 25ur9n9041) (naftifine - unii:4fb1ton47a) - naftifine hydrochloride gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms trichophyton rubrum, trichophyton mentagrophytes, trichophyton tonsurans1 , epidermophyton floccosum1 . 1 efficacy for this organism in this organ system was studied in fewer than 10 infections. naftifine hydrochloride gel, 1% is contraindicated in individuals who have shown hypersensitivity to any of their components.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - betamethasone dipropionate cream (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate cream (augmented), is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate cream (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate cream (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate cream (augmented) on the smallest area

United States - English - NLM (National Library of Medicine)

laboratoires clarins - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - - helps prevent sunburn. - if used as directed with other sun protection measures (see directions) , decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - pyridoxine hydrochloride injection is effective for the treatment of pyridoxine deficiency as seen in the following: inadequate dietary intake. drug-induced deficiency, as from isoniazid (inh) or oral contraceptives. inborn errors of metabolism, e.g., vitamin b6 dependent convulsions or vitamin b6 responsive anemia. the parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. it is also indicated when gastrointestinal absorption is impaired. a history of sensitivity to pyridoxine or to any of the ingredients in pyridoxine hydrochloride injection, usp is a contraindication. symptoms of dependence have been noted in adults given only 200 mg daily, followed by withdrawal.

United States - English - NLM (National Library of Medicine)

mallinckrodt, inc. - methadone hydrochloride (unii: 229809935b) (methadone - unii:uc6vbe7v1z) - methadone hydrochloride 1 g in 1 g - 1.  for detoxification treatment of opioid addiction (heroin or other morphine-like drugs). 2.  for maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. conditions for distribution and use of methadone products for the treatment of opioid addiction code of federal regulations, title 42, sec 8. methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the substance abuse and mental health services administration and approved by the designated state authority. certified treatment programs shall dispense and use methadone in oral form only and according to the treatment requirements stipulated in the federal opioid treatment standards (42 cfr 8.12). see below for important regulatory exceptions to the general requiremen

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults. limitations of use: safety and effectiveness of mesalamine delayed-release tablets beyond 6 weeks have not been established. mesalamine delayed-release tablets are contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of mesalamine delayed-release tablets [see warnings and precautions (5.3), adverse reactions (6.2), and description (11)] . risk summary limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk. no fetal harm was observed in animal reproduction studies of mesalamine in rats and rabbits at oral doses approximately 0.97 times (rat) and 1.95 times (rabbit) the recommended human dose [see data ]. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. in the u.s. general population, the estimated back

United States - English - NLM (National Library of Medicine)

greenstone llc - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone is indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and trea

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - inspra is indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi). inspra is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of